Oncology R&D: Expanding the Role of Economics to Aid Public Policy

肿瘤学R

基本信息

  • 批准号:
    7937073
  • 负责人:
  • 金额:
    $ 13.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-23 至 2014-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Three decades of cancer research has produced insights that have dramatically reduced morbidity and mortality for some forms of cancer and has great potential to produce more success (1). The development of targeted approaches to prevent and treat cancer is primarily the result of substantial public investments in basic science and research and development (R&D) in translational clinical trials (2). In the face of high and growing treatment costs (3,4), increasing trial failure rates and spending (5), and local and federal budgetary deficits (6,7) public agencies that fund clinical trials need empirical evidence of the value of these investments to inform innovation and reimbursement policy and systematically identify, prioritize and design future clinical trials (8,9,10,11,12,13). The growth in investment by for-profit biopharmaceutical firms in R&D over the past decades (14) has highlighted the challenge of thoughtful evaluation and planning of the public's resources and the need for a rigorous and systematic evidence base in pursuing future R&D. Economic theory provides a rigorous framework that may aid the translation of advances in basic science into clinical practice (15). Methods have been developed to retrospectively evaluate and prospectively identify, prioritize and design clinical trials (16,17,18,19,20,21). To date, little work has investigated how these methods applied to the unique context of oncology may provide a systematic empirical base for public decision making. My long term research agenda is focused on applying economic methods to address key policy concerns in the financing and organization of oncology clinical trials and practice and ultimately produce practical tools that public decision makers may use to identify and prioritize R&D investments. I am applying for this career development award to afford me the opportunity to gain training in critical areas I require to pursue my long term agenda. The central aspect of my plan is the pursuit of three research projects using advanced economic methods aimed at informing 3 key policy questions. The empirical pursuit of these projects requires focus on specific examples of recent oncology R&D and employs cost benefit analysis, cost-effectiveness analysis, value of information methods and net present value techniques. Although the application of these methods to specific examples cannot definitively answer broad questions, the completion of these projects will prepare me (and hopefully others) for future work aimed at developing a rigorous empirical base for public decision-making in the financing and organization of oncology treatment innovation. I hope that the results of these projects will be of immediate interest to policy making and academic communities. The award is critical to establishing myself as an economist with expertise in the economics of oncology and translational medicine and to producing key results responsive to public policy maker needs.
描述(由申请人提供):三十年的癌症研究产生了见解,这些见解大大降低了某些形式的癌症的发病率和死亡率,并且具有巨大的成功潜力(1)。预防和治疗癌症的有针对性方法的开发主要是转化临床试验中基础科学和研发(R&D)的大量公共投资的结果(2)。 In the face of high and growing treatment costs (3,4), increasing trial failure rates and spending (5), and local and federal budgetary deficits (6,7) public agencies that fund clinical trials need empirical evidence of the value of these investments to inform innovation and reimbursement policy and systematically identify, prioritize and design future clinical trials (8,9,10,11,12,13)​​.在过去的几十年中,营利性生物制药公司在研发中的投资增长(14)强调了对公众资源的周到评估和计划的挑战,以及在追求未来研发的严格和系统性证据基础的需求。 经济理论提供了一个严格的框架,可以帮助将基础科学进步转化为临床实践(15)。已经开发了回顾性评估和前瞻性识别,优先级和设计临床试验的方法(16,17,18,19,20,21)。迄今为止,很少的工作已经调查了这些方法如何应用于肿瘤学的独特背景可能为公共决策提供系统的经验基础。我的长期研究议程专注于应用经济方法来解决肿瘤学临床试验和实践融资和组织中的关键政策问题,并最终生产出公共决策者可能用来识别和优先考虑研发投资的实用工具。 我正在申请这一职业发展奖,以使我有机会在需要长期议程的关键领域获得培训。我计划的主要方面是使用旨在告知3个关键政策问题的先进经济方法对三个研究项目的追求。对这些项目的经验追求需要关注最近肿瘤研究的具体例子,并采用成本收益分析,成本效益分析,信息方法的价值和净现值技术。 尽管这些方法将这些方法应用于特定的例子不能明确回答广泛的问题,但这些项目的完成将使我(并希望其他人)为未来的工作做好准备,旨在为融资和组织肿瘤治疗创新的融资和组织建立严格的经验基础。我希望这些项目的结果将对政策制定和学术社区产生直接的兴趣。该奖项对于确立自己的经济学家至关重要,在肿瘤学和转化医学经济学方面具有专业知识,并为响应公共政策制定者需求做出响应的关键结果。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Rena Marie Conti其他文献

Rena Marie Conti的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Rena Marie Conti', 18)}}的其他基金

Oncology R&D: Expanding the Role of Economics to Aid Public Policy
肿瘤学R
  • 批准号:
    8123446
  • 财政年份:
    2009
  • 资助金额:
    $ 13.38万
  • 项目类别:
Oncology R&D: Expanding the Role of Economics to Aid Public Policy
肿瘤学R
  • 批准号:
    7789677
  • 财政年份:
    2009
  • 资助金额:
    $ 13.38万
  • 项目类别:
Oncology R&D: Expanding the Role of Economics to Aid Public Policy
肿瘤学R
  • 批准号:
    8326740
  • 财政年份:
    2009
  • 资助金额:
    $ 13.38万
  • 项目类别:
Oncology R&D: Expanding the Role of Economics to Aid Public Policy
肿瘤学R
  • 批准号:
    8547622
  • 财政年份:
    2009
  • 资助金额:
    $ 13.38万
  • 项目类别:
The Economic Value of New Treatments for Depression
抑郁症新疗法的经济价值
  • 批准号:
    6938475
  • 财政年份:
    2003
  • 资助金额:
    $ 13.38万
  • 项目类别:
The Economic Value of New Treatments for Depression
抑郁症新疗法的经济价值
  • 批准号:
    6738853
  • 财政年份:
    2003
  • 资助金额:
    $ 13.38万
  • 项目类别:
The Economic Value of New Treatments for Depression
抑郁症新疗法的经济价值
  • 批准号:
    6868865
  • 财政年份:
    2003
  • 资助金额:
    $ 13.38万
  • 项目类别:

相似国自然基金

时空序列驱动的神经形态视觉目标识别算法研究
  • 批准号:
    61906126
  • 批准年份:
    2019
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
  • 批准号:
    41901325
  • 批准年份:
    2019
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
  • 批准号:
    61802133
  • 批准年份:
    2018
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
  • 批准号:
    61872252
  • 批准年份:
    2018
  • 资助金额:
    64.0 万元
  • 项目类别:
    面上项目
针对内存攻击对象的内存安全防御技术研究
  • 批准号:
    61802432
  • 批准年份:
    2018
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Prostate Specific Anti-androgen Therapy for Localized Prostate Cancer
前列腺特异性抗雄激素疗法治疗局限性前列腺癌
  • 批准号:
    10760194
  • 财政年份:
    2023
  • 资助金额:
    $ 13.38万
  • 项目类别:
Regulatory Mechanisms Addressing Diabetic Vasculopathy
解决糖尿病血管病变的调节机制
  • 批准号:
    10718850
  • 财政年份:
    2023
  • 资助金额:
    $ 13.38万
  • 项目类别:
Brain Networks of Turning Performance with Aging and Stroke
衰老和中风影响转向性能的大脑网络
  • 批准号:
    10536898
  • 财政年份:
    2022
  • 资助金额:
    $ 13.38万
  • 项目类别:
Subclonal heterogeneity and outcome disparities in Triple-Negative Breast Cancer among African Americans
非裔美国人三阴性乳腺癌的亚克隆异质性和结果差异
  • 批准号:
    10596525
  • 财政年份:
    2022
  • 资助金额:
    $ 13.38万
  • 项目类别:
Neonatal Opioid Withdrawal Syndrome (NOWS) in Kentucky: Improving Outcomes for Infants
肯塔基州新生儿阿片类药物戒断综合症 (NOWS):改善婴儿的预后
  • 批准号:
    10380355
  • 财政年份:
    2021
  • 资助金额:
    $ 13.38万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了